SEC For	m 4 FORM -	4 UI			TES :	SEC	UR	ITIE	S AN	DE	XCHAI	NGE	со	MMI	SSIO	N				
			Washington, D.C. 20549											OMB APPROVA						
to Section 16. Form 4 or Form 5 obligations may continue. See						IT OF CHANGES IN BENEFICIAL OWN pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									SHIP	Estin	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [VRTX]									(Che	5. Relationship of Reporting Person(s) to Issue (Check all applicable) Director 10% Owner X Officer (give title Other (spec below) below)				wner (specify	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 08/09/2022									SVP, General Counsel					
(Street) BOSTON MA 02210					4. lf /	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 					
(City) (State) (Zip)						tive Securities Acquired, Disposed of, or Benefi														
1. Title of Security (Instr. 3) (Month/Date)				ction	tion 2A. Deemed Execution Date,			3. Transaction Code (Instr. 5)			es Acquired (A) or Df (D) (Instr. 3, 4 and			5. Amo Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) c (D)	Pr P	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 08/09/2					2022			S ⁽¹⁾		946	D		\$300) 13,388			D			
		Tal									osed of, onvertib				Ownee	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) if any (Month/Day/Year) ve		4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Disp of (D	osed) r. 3, 4	Expiration (Month/Day		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4) Amount or Number of Title Shares		unt ber	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		

Explanation of Responses:

1. Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1.

Remarks:

/s/ Joy Liu

08/10/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.